title: Prediction of the therapeutic effect of dienogest in ovarian endometrial cysts using the apparent diffusion coefficient.
abstract: The purpose of this study was to investigate whether apparent diffusion coefficient (ADC) mean values can be used for predicting the treatment response in ovarian endometrial cyst patients with dienogest (DNG) administration. Eighteen patients received DNG (2 mg/day, orally) for 60 days, among whom 26 ovarian endometrial cysts were retrospectively identified. Mean ADC values of individual ovarian endometrial cysts were obtained by ADC maps inside the tumor. There was a significant correlation between ADC values and reduction ratio. When calculating the mean ADC values for three groups; more than 50%, 50-25% and less than 25%, ADC values significantly increased with increasing reduction ratio; 2.05 × 10(-3)mm(2)/s, 1.28 × 10(-3)mm(2)/s and 0.94 × 10(-3)mm(2)/s, respectively (p = 0.0180). Multiple regression analysis by reduction ratio (%), ADC mean values (× 10(-3)mm(2)/s), tumor longest diameter (cm) and CA125 (U/ml) revealed that tumor reduction ratio by DNG administration could be predicted by the following equation; R = 19.3 + 24.0x - 0.4y + 0.1z (R: Reduction ratio, x: ADC mean, y: Longest diameter, z: CA125). In conclusion, the ADC mean value is useful for the prediction of the treatment response in ovarian endometrial cyst patients with DNG administration.
authors.affiliation: Department of Obstetrics and Gynecology, Sapporo Medical University , Sapporo , Japan and.
authors.forename: Motoki
authors.initials: M
authors.lastname: Matsuura
authors.forename: Masato
authors.initials: M
authors.lastname: Tamate
authors.forename: Yuta
authors.initials: Y
authors.lastname: Tabuchi
authors.forename: Sakura
authors.initials: S
authors.lastname: Takada
authors.forename: Ryoichi
authors.initials: R
authors.lastname: Tanaka
authors.forename: Masahiro
authors.initials: M
authors.lastname: Iwasaki
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Saito
mesh_terms: D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D054316:Biomarkers, Pharmacological / Q000032:analysis*; D004058:Diffusion; D038524:Diffusion Magnetic Resonance Imaging; D004715:Endometriosis / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009277:Nandrolone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010048:Ovarian Cysts / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology; D011237:Predictive Value of Tests; D011379:Prognosis; D012189:Retrospective Studies
chemical_list: D018931:Antineoplastic Agents, Hormonal; D054316:Biomarkers, Pharmacological; C023635:dienogest; D009277:Nandrolone
keywords: ADC; MR imaging; dienogest; endometriosis; ovarian endometrial cyst